Market Overview

UPDATE: Bank of America Raises PO to $40 on Integra Lifesciences

Related IART
UPDATE: Integra LifeSciences Announces FDA Clearance And Controlled Market Release Of Expandable Interbody System For Spinal Surgery
Integra LifeSciences Introduces Integra Pocket Strip And Integra Shaped Strip DBM Implants
EMCORE Selling Space Solar Business to Veritas Capital (Fox Business)

Bank of America Merrill Lynch reiterates a Neutral rating on Integra Lifesciences (NASDAQ: IART) and raises its price objective from $36 to $40.

Bank of America Merrill Lynch comments, “Raising PO to $40 We are raising our PO on IART to $40 from $36 primarily due to the recent signs of stabilization and/or strength in IART's most important orthopedic growth markets (extremities/spine) that we have documented in recent notes on Biomet and ZMH. Additionally, IART, like many US-focused small cap device names, would benefit in a disproportionate way if the Supreme Court declares President Obama's healthcare reform law unconstitutional this week (a decision is expected Thursday 6/28).”

Integra Lifesciences closed at $35.74 yesterday.

Latest Ratings for IART

DateFirmActionFromTo
Aug 2014OppenheimerMaintainsOutperform
May 2014OppenheimerMaintainsOutperform
Apr 2014Lake Street CapitalInitiates Coverage onBuy

View More Analyst Ratings for IART
View the Latest Analyst Ratings

Posted-In: Bank of AmericaAnalyst Color News Price Target Politics Legal Analyst Ratings General

 

Related Articles (IART)

Around the Web, We're Loving...

Get Benzinga's Newsletters